OverviewChartNewsTraderScreen

Morgan Stanley Knock-Out BGNE/  DE000MB80XF1  /

Stuttgart
22/05/2024  10:20:29 Chg.+0.23 Bid16:10:32 Ask16:10:32 Underlying Strike price Expiration date Option type
6.57EUR +3.63% 6.54
Bid Size: 3,750		 6.70
Ask Size: 3,750		 BeiGene Ltd 99.4163 - 31/12/2078 Call
GlobeNewswire 06/08/2020 BeiGene Reports Second Quarter 2020 Financial Results
GlobeNewswire 05/08/2020 BeiGene Announces Data on Tislelizumab and Pamiparib to Be Presented at the 2020 European Society fo...
GlobeNewswire 27/07/2020 Priority Review Granted to BeiGene’s New Drug Application of Pamiparib in Ovarian Cancer in China
GlobeNewswire 17/07/2020 BeiGene Announces Acceptance of a New Drug Application of Pamiparib in Ovarian Cancer in China
GlobeNewswire 15/07/2020 BeiGene Announces Closing of Approximately $2.08 Billion Registered Direct Offering
GlobeNewswire 13/07/2020 BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering
GlobeNewswire 02/07/2020 BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipe...
GlobeNewswire 02/07/2020 BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients wit...
GlobeNewswire 01/07/2020 BeiGene Announces Appointment of Angus Grant as Chief Business Executive
GlobeNewswire 01/07/2020 BeiGene Begins Commercializing XGEVA® (Denosumab) in China
GlobeNewswire 19/06/2020 BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination ...
GlobeNewswire 18/06/2020 BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application fo...
GlobeNewswire 12/06/2020 BeiGene Presents Clinical Data on Zanubrutinib and Tislelizumab at the 25th European Hematology Asso...
GlobeNewswire 05/06/2020 BeiGene to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
GlobeNewswire 03/06/2020 BeiGene Announces the Approval of BRUKINSA™ (Zanubrutinib) in China for Patients with Relapsed/Refra...
GlobeNewswire 29/05/2020 BeiGene Presents Updated Head to Head Results from Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Pa...
GlobeNewswire 29/05/2020 BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Patien...
GlobeNewswire 26/05/2020 BeiGene to Host Investor Conference Call and Webcast to Discuss Clinical Study Results Presented at ...
GlobeNewswire 21/05/2020 BeiGene and Medison Pharma Announce Exclusive Distribution Agreement and Acceptance of New Drug Appl...
GlobeNewswire 20/05/2020 BeiGene to Present at the Bernstein 36th Annual Strategic Decisions Conference
GlobeNewswire 15/05/2020 BeiGene Announces Clinical and Preclinical Data to Be Presented at the 2020 American Association for...
GlobeNewswire 14/05/2020 BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA™ (Zanubrutinib) and Tislelizumab to Be ...
GlobeNewswire 11/05/2020 BeiGene Reports First Quarter 2020 Financial Results
GlobeNewswire 29/04/2020 BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (A...
GlobeNewswire 20/04/2020 BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination ...